Home

ANNE VANLENT

CIK 1229243 · Exec VP & CFO · last filed 2026-06-04

ANNE VANLENT is an Exec VP & CFO who has filed 59 SEC Form 4 insider transactions across 12 companies since 2007. The most recent filing, for TRVI, was dated Jun 4, 2026. Across all open-market trades the lifetime net is −$130.4K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $686.3K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$686.3K

Companies

12

Total Filings

59

Lifetime Open-Market Net

-$130.4K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
TRVI Director 20,983 $18.36 $385.2K $50.0K 10 2026-06-04
APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted Director — $0.39 — $0 9 2022-12-01
Vaxart, Inc. (VXRT) Delisted Director — $0.32 — $0 1 2019-06-14
AVIR Director — $4.77 — $0 2 2017-05-22
NOVELION THERAPEUTICS INC. (NVLN) Delisted Director — — — $0 1 2016-12-27
Aegerion Pharmaceuticals, Inc. (AEGR) Delisted Director 0 — — $0 3 2016-11-30
Vaxart, Inc. (BOTA) Delisted Director 35,000 — — $76.9K 4 2015-08-13
ONTX Director — $13.46 — $0 3 2015-06-17
Ocera Therapeutics, Inc. (TZYM) Delisted Director — — — $0 2 2012-08-09
IART Director 16,956 $17.75 $301.1K -$250.3K 8 2012-05-21
PENWEST PHARMACEUTICALS CO (PPCO) Delisted Director 0 — — -$7.0K 8 2010-09-22
BARRIER THERAPEUTICS INC (BTRX) Delisted Exec VP & CFO 148,852 — — $0 2 2008-03-17

Recent Filings

59 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-04 TRVI Grant (A) — $0 EDGAR
2025-06-13 TRVI Grant (A) — $0 EDGAR
2024-06-14 TRVI Grant (A) — $0 EDGAR
2023-06-30 TRVI Grant (A) — $0 EDGAR
2022-12-01 APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted Disp (D) — $0 EDGAR
2022-07-01 TRVI Grant (A) — $0 EDGAR
2022-06-23 TRVI Grant (A) — $0 EDGAR
2021-12-02 APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted Grant (A) — $0 EDGAR
2021-06-17 TRVI Grant (A) — $0 EDGAR
2020-12-18 APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 59
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.